12-Hydroxyeicosatetraenoic acid

12-Hydroxyeicosatetraenoic acid
Names
IUPAC name
(5Z,8Z,10E,12S,14Z)-12-Hydroxyicosa-5,8,10,14-tetraenoic acid
Other names
12-HETE; 12(S)-HETE
Identifiers
54397-83-0 N
3D model (Jmol) Interactive image
Interactive image
ChEBI CHEBI:34146 YesY
ChemSpider 4446279 YesY
3404
PubChem 5283155
Properties
C20H32O3
Molar mass 320.47 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

12-Hydroxyeicosatetraenoic acid (12-HETE) is a derivative of the 20 carbon polyunsaturated fatty acid, arachidonic acid, containing a Hydroxyl residue at carbon 12 and a 5Z,8Z,10E,14Z Cis–trans isomerism configuration (Z=cis, E=trans) in its four double bonds. It was first found as a product of arachidonic acid metabolism made by human and bovine platelets through their 12S-lipoxygenase (i.e. ALOX12) enzyme(s).[1][2] However, the term 12-HETE is ambiquous in that it has been used to indicate not only the initially detected "S" stereoisomer, 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12(S)-HETE or 12S-HETE), made by platelets, but also the later detected "R" stereoisomer, 12(R)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (also termed 12(R)-HETE or 12R-HETE) made by other tissues through their 12R-lipoxygenase enzyme, ALOX12B. The two isomers, either directly or after being further metabolized, have been suggested to be involved in a variety of human physiological and pathological reactions. Unlike hormones which are secreted by cells, travel in the circulation to alter the behavior of distant cells, and thereby act as Endocrine signalling agents, these arachidonic acid metabolites act locally as Autocrine signalling and/or Paracrine signaling agents to regulate the behavior of their cells of origin or of nearby cells, respectively. In these roles, they may amplify or dampen, expand or contract cellular and tissue responses to disturbances.

Production

In humans, Arachidonate 12-lipoxygenase (12-LO, 12-LOX, ALO12, or platelet type 12-lipoxygenase) is encoded by the ALOX12 gene and expressed primarily in platelets and skin. ALOX12 metabolizes arachidonic acid almost exclusively to 12(S)-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12(S)-HpETE or 12S-HpETE).[3] Arachidonate 15-lipoxygenase-1 (15-LO-1, 15-LOX-1, ALOX15), which is expressed in far more tissues that ALOX12, metabolizes arachidonic acid primarily to 15(S)-HpETE along with other metabolites of the 15-Hydroxyicosatetraenoic acid family; during this metabolism, however, ALOX15 also forms 12(S)-HpETE as a minor product.[4] Arachidonate 12-lipoxygenase, 12R type, also termed 12RLOX and encoded by the ALOX12B gene, is expressed primarily in skin and cornea; it metabolizes arachidonic acid to 12(R)-HpETE.[5][6] Cytochrome P450 enzymes convert arachidonic acid to a variety of hydroperoxy, epoxy, and dihydroxy derivatives including racemic mixtures of 12(S)-HpETE and 12(R)-HpETE or 12(S)-HETE and 12(R)-HETE; the R stereoisomer predominates in these mixtures.[5][7][7][8] The initial 12(S)-HpETE and 12(R)-HpETE products, regardless of their pathway of formation, are rapidly reduced to 12(S)-HETE and 12(R)-HETE, respectively, by ubiquitous cellular peroxidases, including in particular Glutathione peroxidases[9] or, alternatively, are further metabolized as described below.

Sub-primate mammals, such as the mouse, rat, rabbit, cow, and pig, express platelet type 12-lipoxygenase but also a leukocyte type 12-lipoxygenase (also termed 12/15-lipoxygenase, 12/15-LOX or 12/15-LO) which is an ortholog of, and metabolically equivalent to, human 15-LO-1 in that it forms predominantly 15(S)-HpETE with 12(S)-HpETE as a minor product.[3][10] Mice also express an epidermal type 15-lipoxygenase (e-12LO) which has 50.8% amino acid sequence identity to human 15-LOX-2 and 49.3% sequence indetity to mouse Arachidonate 8-lipoxygenase.[11] Mouse e-12LO metabolizes arachidonic acid predominantly to 12(S)-HETE and to a lesser extent 15(S)-HETE.[12]

Sub-human primates, although not extensively examined, appear to have 12-lipoxygenase expression patterns that resemble those of sub-primate mammals or humans depending on the closeness of there genetic relateness to these species.[13]

Further metabolism

In human (and mouse) skin epidermis, 12(R)-HpETE is metabolized by Epidermis-type lipoxygenase, i.e. eLOX3 (encoded by the ALOXE3 gene), to two products: a) a specific hepoxilin, 8R-hydroxy-11R,12R-epoxy-5Z,9E,14Z-eicosatetraenoic acid (i.e. 8R-hydroxy,11R,12R-epoxy-hepoxilin A3 or 8R-OH,11R,12R-epoxy-hepoxilin A3) and b) 12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid (12-oxo-HETE, 12-oxoETE, 12-Keto-ETE, or 12-KETE); 8R-hydroxy,11R,12R-epoxy-hepoxilin A3 is further metabolized by soluble Epoxide hydrolase 2 (sEH) to 8R,11R,12R-trihydroxy-5Z,9E,14Z-eicosatetraenoic acid.[14] 12(R)-HpETE also spontaneously decomposes to a mixture of hepoxilins and trihydroxy-eicosatetraenoic acids that possess R or S hydroxy and epoxy residues at various sites while 8R-hydroxy,11R,12R-epoxy-hepoxilin A3 spontaneously decomposes to 8R,11R,12R-trihydroxy-5Z,9E,14Z-eicosatetraenoic acid.[14] These decompositions may occur during tissue isolation procedures. Recent studies indicate that the metabolism by ALOXE3 of the R stereoisomer of 12-HpETE made by ALOX12B and therefore possibly the S stereoisomer of 12-HpETE made by ALOX12 or ALOX15 is responsible for forming various hepoxilins in the epidermis of human and mouse skin and tongue and possibly other tissues.[15][16]

Human skin metabolizes 12(S)-HpETE in reactions strictly analogous to those of 12(R)-HpETE; it metabolized 12(S)-HpETE by eLOX3 to 8R-hydroxy-11S,12S-epoxy-5Z,9E,14Z-eicosatetraenoic acid and 12-oxo-ETE, with the former product then being metabolized by sEH to 8R,11S,12S-trihydroxy-5Z,9E,14Z-eicosatetraenoic acid. 12(S)-HpETE also spontaneously decomposes to a mixture of hepoxilins and trihydroxy-eicosatetraenoic acids (trioxillins) that possess R or S hydroxy and R,S or S,R epoxide residues at various sites while 8R-hydroxy,11S,12S-epoxy-hepoxilin A3 spontaneously decomposes to 8R,11S,12S-trihydroxy-5Z,9E,14Z-eicosatetraenoic acid.[14]

In other tissues and animal species, numerous hepoxilins form but the hepoxilin synthase activity responsible for their formation is variable. (Hepoxilin A3 [8R/S-hydroxy-11,12-epoxy-5Z,9E,14Z-eicosatrienoic acid] and hepoxilin B3 [10(R/S-hydroxy-11,12-epxoy-5Z,8Z,14Z-eicosatrienoic acid] refer to a mixture of Diastereomers and⁄or Enantiomers derived from arachidonic acid.[9][15]) Cultured RINm5F rat Insulinoma cells convert 12(S)-HpETE to hepoxilin A3 in a reaction that is comletely dependent on, and co-localizes with, the cells' leukocyte type 12-LOX; furthermore, recombinant rat and porcine leukocyte type 12-LOX as well as human platelet type 12-LOX metabolize 12(S)-HpETE to hepoxylin A3.[17] However, transfection of HEK293 human embryonic kidney cells with each of the 6 rat lipoxygenases, including rat eLOX3, found that hepoxilin B3 production required eLOX3; furthermore, the development of inflammation-induced tactile pain hypersensitivity (hyperesthesia; tactile Allodynia) in rats required eLOX3-dependent production of hepoxilin B3 by spinal tissue.[18] Thus, the production of hepoxilins from 12(S)-HpETE may result from the intrinsic activity of platelet or leukocyte type 12-LOX's, require eLOX3, or even result from 12(S)-HpETE spontaneous (and perhaps artifactual) decomposition during isolation. The majority of reports on hepoxilin formation have not defined the pathways evolved.

Human and other mammalian cytochome P450 enzymes convert 12(S)-HpETE to 12-oxo-ETE.

12-HETE (steroisomer not determined), 12(S)-HETE, 12-oxo-ETE, hepoxilin B3, and trioxilin B3 are found in the sn-2 position of phospholipids isolated from normal human epidermis and human psoriatic scales.[19][20] This indicates that the metabolites are acylated into the sn-2 position after being formed and/or directly produced by the metabolism of the arachidonic acid at the sn-2 position of these phospholipids. These acylation reactions may sequester and thereby inactivate or store the metabolites for release during cell stimulation.[21]

12(S)-HETE and 12(R)-HETE are converted to 12-oxo-ETE by microsomal NAD+-dependent 12-hydroxyeicosanoid dehdrogenase in porcine polymophonuclear leukocytes; a similar pathway may be active in rabbit corneal epitheleum, cow corneal epitheleum, and mouse keratinocytes although this pathway has not been described in human tissues.[22]

12-oxo-ETE is metabolised by cytoslic NADH-dependent 12-oxoeicosinoid Δ10-reductase to 12-oxo-5Z,8Z,14Z-eicosatreienoic acid (12-oxo-ETrE); 12-ketoreductase may then reduce this 12-oxo-ETrE to 12(R)-hydroxy-5Z,8Z,14Z-eicosatreienoic acid (12(R)-HETrE) and to a lesser extent 12(S)-hydroxy-5Z,8Z,14Z-eicosatreienoic acid (12(S)-HETrE).[22]

Receptor targets and mechanisms of action

The G protein-coupled receptor, GPR31, cloned from PC3 human prostate cancer cell line is a high affinity (Kd=4.8 nM) receptor for 12(S)-HETE; GPR31 does not bind 12(R)-HETE and has relatively little affinity for 5(S)-HETE or 15(S)-HETE.[23] GPR31 mRNA is expressed at low levels in several human cell lines including K562 cells (human myelogenous leukemia cell line), Jurkat cells, (T lymphocye cell line), Hut78 cells (T cell lymphoma cell line), HEK 293 cells (primary embryonic kidney cell line), MCF7 cells (mammary adenocarcinoma cell line), and EJ cells (bladder carcinoma cell line). This mRNA appears to be more highly expressed in PC3 and DU145 prostate cancer cell lines as well as in human umbilical vein endothelial cells (HUVEC), human umbilical vein endothelial cells (HUVEC), human brain microvascular endothelial cells (HBMEC), and human pulmonary aortic endothelial cells (HPAC).[23] In PC-3 prostate cancer cells, GPR31 receptor mediates the action of 12(S)-HETE in activating the Mitogen-activated protein kinase kinase/Extracellular signal-regulated kinases-1/2 pathway and NFκB pathway that lead to cell growth and other functions.[23] Studies have not yet determined the role, if any, in GPR31 receptor in the action of 12(S)-HETE in other cell types.

A G protein-coupled receptor for the 5(S),12(R)-dihydroxy metabolite of aracidonic acid, Leukotriene B4, vis., Leukotriene B4 receptor 2 (BLT2), but not its Leukotriene B4 receptor 1, mediates responses to 12(S)-HETE, 12(R)-HETE, and 12-oxo-ETE in many cell types.[24] Based on the effects of LTB4 receptor antagonists, for example, leukotriene B4 receptor 2 mediates: the rise in cytosolic Ca2+ concentration (a key signal for cell activation) in human neutrophils[25][26][27] and the rise in cytosolic Ca2+ concentration and chemotaxis in Chinese hamstery ovarian cells[28] stimlated by 12(S)-HETE, 12(R)-HETE, and/or 12-oxo-ETE; the itch response to 12(S)-HETE[29] and PMN inflammatory infiltration response to 12(R)-HETE[30] triggered by the injection the these metabolites into the skin of mice and guinea pigs, respectively; and an in vitro angiogenic response by Human umbilical vein endothelial cells (HUVEC) and in vivo angiogenic response by mice to 12(S)-HETE.[31] The BLT2 receptor, in contrast to the GPR31 receptor, appears to be expressed at a high level in a wide range of tissues including neutrophils, eosinophils, monocytes, spleen, liver, and ovary.[32] However, 12-Hydroxyheptadecatrienoic acid (i.e. 12-(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid or 12-HHT), a product made when prostaglandin H2 is metablized to Thromboxane A2 by Thromboxane synthase or spontaneously rearranges non-enzymatically (see 12-Hydroxyheptadecatrienoic acid) is the most potent BLT2 receptor agonist detected to date.[33] To clarify the role of BLT2 versus GPC31 receptors in responses to 12(S)-HETE, and the role(s) of LTB4, 12(S)-HETE, versus 12-HHT in BLT2-mediated responses, it will be necessary to determine: a) if leukotriene B4 interacts with the GPR31 receptor; b) if BLT2 receptor antagonists interfere with the GPR31 receptor; and c) the relative concentrations and availability of LTB4, 12(S)-HETE, and 12-HHT in tissues exhibiting BLT2-dependent responses. Ultimately, both receptors and all three ligands may prove to be responsible for some tissue responses in vivo.

12(S)-HETE and 12(R)-HETE bind to and act as Competitive antagonists of the Thromboxane receptor which mediates the actions of Thromboxane A2 and Prostaglandin H2.[34][35] This antagonistic activity was responsible for the ability of 12(S)-HETE and 12(R)-HETE to relax mouse mesenteric arteries pre-constricted with a thromboxane A2 mimetic, U46619.[36]

12(S)-HETE binds with high affinity to a 50 kilodalton (Kda) subunit of a 650 kDa cytosolic and nuclear protein complex.[37]

Activities and possible clinical significance

Inflammation and inflammatory diseases

12(S)-HpETE, 12(R)-HETE, racemic mixtures of these 12-HETEs, and/or 12-oxo-ETE stimulate: a) the directed migration (chemotaxis) of human, rat, and rabbit neutrophils as well as rabbit macrophages;[38][39][40] b) human neutrophils to adhere to each other (i.e. aggregate) and in cooperation with Tumor necrosis factor alpha or Platelet-activating factor, to release their granule-bound enzymes;[41] c) the binding of human vascular epithelial cells to human monocytes;[42][43] d) DNA synthesis and mitogenesis in the immortalized human keratinocyte cell line HaCaT;[44] and e) when injected in the skin of human volunteers, the extravasation and local accumulation of circulating blood neutrophils and mononuclear cells.[45][46] These results suggest these metabolites contribute to the inflammation that occurs as sites where they are formed in abnormal amounts such as in human rheumatoid arthritis, Inflammatory bowel disease, Contact dermatitis, psoriasis, various forms of Ichthyosis including Congenital ichthyosiform erythroderma, and corneal inflammatory diseases.[15][47][48][49][50][51] Since BLT2 appears to mediate the responses of leukocytes to 12(S)-HpETE, 12(S)-HETE, 12(R)-HETE, and 12-oxo-ETE but GPR31 is expressed by various other cells (e.g. vascular endothelium) involved in inflammation, the pro-inflammatory actions of 12-HETE in humans may involve both types of G protein-coupled receptors.

Itch perception

12(S)-HpETE and 12(S)-HETE induce itching responses when injected into the skin of mice; this has led to the suggestion that these metabolites contribute to the itching (i.e. clinical pruritus) which accompanies such conditions as atopic dermatitis, contact dermatitis, urticaria, chronic renal failure, and cholestasis.[29][52] Since it mediates 12(S)-HETE-induced itching in the mouse model,[29] BLT2 rather than GPR31 may mediate human itch in these reactions.

Cancer

Prostate cancer

12-HETE (stereoisomer not defined) is the dominant arachidonic acid metabolite in cultured PC3 human prostate cancer cells and its levels in human prostate cancer tissue exceed by >9-fold its levels in normal human prostate tissue.[53] Furthermore, 12(S)-HETE a) increases the expression of Alpha-v beta-5 cell surface adhesion molecule and associated with this the survival of cultured PC3 cells;[54] b) promotes the phosphorylation of retinoblastoma protein to inhibit its tumor suppressor function while promoting the proliferation of cultured PC3 cells;[55] c) stimulates PC3 cells to activate the Mitogen-activated protein kinase kinase/extracellular signal-regulated kinases-1/2 pathway and the NFκB pathways that lead to cell proliferation;[23] d) reverses the apoptosis-inducing (i.e. cell-killing) effect of pharmacologically inhibiting 12-LO in cultured DU145 human prostate cancer cells;[56] e) promotes the induction of cyclooxygenase-1 and thereby the synthesis of this enzyme's growth-promoting arachidonic acid metabolite, PGE2, in cultured PC3 and LNCaP human prostate cancer cells;[57] and f) induces cultured PC3 cells to express Vascular endothelial growth factor (VEGF), a protein that stimulates the formation of the microvasclature which assists in the metastasis of cancer.[58] These results suggest that the 12(S)-HETE made by prostate cancer tissues serves to promote the growth and spread of this cancer. Since it mediates the action of 12(S)-HETE in stimulating cultured PC3 cells to activate the Mitogen-activated protein kinase kinase/Extracellular signal-regulated kinases-1/2 pathway and NFκB pathways, the GPR31 receptor may contribute to the pro-malignant activity of 12(S)-HETE. However, LNCaP and PC3 cells also express BLT2 receptors; in LNCaP cells, BLT2 receptors are positively linked (i.e. stimulate the expression of) to the growth- and metastasis-promoting androgen receptor;[59] in PC3 cells, BLT2 receptors stimulate the NF-κB pathway to inhibit the apoptosis caused by cell detachment from surfaces (i.e. Anoikis;[60] and, in BLT2-overexpressing PWR-1E non-malignant prostate cells, 12(S)-HETE diminish anoikis-induced apoptosis.[60] ith occurs. Thus, the role of 12(S)-HETE in human prostate cancer, if any, may involve its activation of one or both of the GPR31 and BLT2 receptors.

Other cancers

Preclinical laboratory studies analogous to those conducted on the pro-malignant effects of 12(S)-HETE and growth-inhibiting effects of blocking 12-HETE production in cultured prostate cancer cell lines, have implicated 12-HETE (stereoisomer sometimes undefined) in cancer cell lines from various other human tissues including those from the liver,[61][62] intestinal epithelium,[63][64] lung,[65] breast,[66][67] skin (Melanoma,[68] ovary,[69] pancrease,[70][71] and possibly bladder.[72] These studies implicate the interaction of 12-HETE with BLT2 receptors in intestinal epithelium cancer cells,[64] and BLT2 receptors in breast, ovary, pancreas, and bladder cancer cells.[72][73][74] While the studies on these tissues have not been as frequent or diverse as those on prostate cancer cell lines, they are suggested to indicate that 12-HETE contributes to the growth or spread of the corresponding cancer in humans.

Diabetes

12(S)-HETE, 12(S)-HpETE, and with far less potency 12(R)-HETE reduced insulin secretion and caused apoptosis in cultured human pancreatic insulin-secreting Beta cell lines and prepared Pancreatic islets.[75][76] TNFα, IL-1β, and IFNγ also reduced insulin secretion in cultured human pancreatic INS-1 beta cells, apparently by inducing the expression of NOX1 (NADPH oxidase 1) and thereby to the production of cell-toxic Reactive oxygen species; these cytokine effects were completely dependent on 12-lipoxygenase and mimicked by 12(S)-HETE but not 12(R)-HETE.[77] 12-lipoxygenase-knockout mice (i.e., mice genetically manipulated to remove the Alox12 [i.e. 12-lipoxygenase gene, see lipoxygenase#mouse lipoxygenases) are resistant to a) streptozotocin-induced, b) high fat diet-induced, and c) autoimmune-induced diabetes.[4][78] Further studies in animal models suggest that the 12S-HETE made by pancreatic beta cells (or possibly alpha cells or other cell types indigenous to or invading the pancreatic islands) orchestrate an local immune response that results in the injury and, when extreme, death of beta cells.[4] These results suggest that the 12-lipoxygenase-12S-HETE pathway is one factor contributing to immunity-based type I diabetes as well as low insulin output type II diabetes.

Blood pressure

12(S)-HETE and 12(S)-HpETE stimulate the dilation of rat mesenteric arteries;[79][80] 12(S)-HETE stimulates the dilation of coronary microvessels in pigs and the mesenteric arteries of mice,[81] one or more of these three metabolites are implicated in the vasolilation of rat basilar artery,[82] 12(R)-HETE and to a slightly lesser extent 12(S)-HETE constrict the renal artery of dogs[83] and 12-HETE (stereoisomer undetermined) is implicated in the angiotensin II-induced arterial hypertension response of human placenta.[84] The vasodilating effect on mouse mesenteric arteries appears due to 12S-HETE's ability to act as a Thromboxane receptor antagonist and thereby block the vasoconstricting actions of thromboxane A2.[85] These results indicate that the cited metabolites have dilating or constricting effects that depend on the arterial vascular site and or species of animal examined; their role in human blood pressure regulation is unclear.

Toxic Effects

Excessive 12-HETE production is implicated in psoriasis[47]

See also

References

  1. ↑ Hamberg, M; Samuelsson, B (1974). "Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets". Proceedings of the National Academy of Sciences of the United States of America. 71 (9): 3400–4. doi:10.1073/pnas.71.9.3400. PMC 433780Freely accessible. PMID 4215079.
  2. ↑ Nugteren, D. H. (1975). "Arachidonate lipoxygenase in blood platelets". Biochimica et biophysica acta. 380 (2): 299–307. doi:10.1016/0005-2760(75)90016-8. PMID 804329.
  3. 1 2 Yoshimoto, T; Takahashi, Y (2002). "Arachidonate 12-lipoxygenases". Prostaglandins & other lipid mediators. 68-69: 245–62. doi:10.1016/s0090-6980(02)00034-5. PMID 12432922.
  4. 1 2 3 Dobrian, A. D.; Lieb, D. C.; Cole, B. K.; Taylor-Fishwick, D. A.; Chakrabarti, S. K.; Nadler, J. L. (2011). "Functional and pathological roles of the 12- and 15-lipoxygenases". Progress in Lipid Research. 50 (1): 115–31. doi:10.1016/j.plipres.2010.10.005. PMC 3012140Freely accessible. PMID 20970452.
  5. 1 2 Oliw, E. H. (1993). "Bis-Allylic hydroxylation of linoleic acid and arachidonic acid by human hepatic monooxygenases". Biochimica et biophysica acta. 1166 (2–3): 258–63. doi:10.1016/0005-2760(93)90106-j. PMID 8443245.
  6. ↑ Schneider, C; Boeglin, W. E.; Brash, A. R. (2002). "Analysis of cyclooxygenase-substrate interactions using stereospecifically-labeled arachidonic acids". Advances in experimental medicine and biology. 507: 49–53. PMID 12664563.
  7. 1 2 Bylund, J; Kunz, T; Valmsen, K; Oliw, E. H. (1998). "Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes". The Journal of pharmacology and experimental therapeutics. 284 (1): 51–60. PMID 9435160.
  8. ↑ Panigrahy, D; Kaipainen, A; Greene, E. R.; Huang, S (2010). "Cytochrome P450-derived eicosanoids: The neglected pathway in cancer". Cancer and Metastasis Reviews. 29 (4): 723–35. doi:10.1007/s10555-010-9264-x. PMC 2962793Freely accessible. PMID 20941528.
  9. 1 2 Pace-Asciak, C. R. (2015). "Pathophysiology of the hepoxilins". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1851 (4): 383–96. doi:10.1016/j.bbalip.2014.09.007. PMID 25240838.
  10. ↑ Collins, J. F.; Hu, Z; Ranganathan, P. N.; Feng, D; Garrick, L. M.; Garrick, M. D.; Browne, R. W. (2008). "Induction of arachidonate 12-lipoxygenase (Alox15) in intestine of iron-deficient rats correlates with the production of biologically active lipid mediators". AJP: Gastrointestinal and Liver Physiology. 294 (4): G948–62. doi:10.1152/ajpgi.00274.2007. PMID 18258795.
  11. ↑ Krieg, P; Kinzig, A; Heidt, M; Marks, F; Fürstenberger, G (1998). "CDNA cloning of a 8-lipoxygenase and a novel epidermis-type lipoxygenase from phorbol ester-treated mouse skin". Biochimica et biophysica acta. 1391 (1): 7–12. doi:10.1016/s0005-2760(97)00214-2. PMID 9518531.
  12. ↑ McDonnell, M; Davis Jr, W; Li, H; Funk, C. D. (2001). "Characterization of the murine epidermal 12/15-lipoxygenase". Prostaglandins & other lipid mediators. 63 (3): 93–107. doi:10.1016/s0090-6980(00)00100-3. PMID 11204741.
  13. ↑ Johannesson, M; Backman, L; Claesson, H. E.; Forsell, P. K. (2010). "Cloning, purification and characterization of non-human primate 12/15-lipoxygenases". Prostaglandins, Leukotrienes and Essential Fatty Acids. 82 (2–3): 121–9. doi:10.1016/j.plefa.2009.11.006. PMID 20106647.
  14. 1 2 3 Valmsen, K; Boeglin, W. E.; Järving, R; Järving, I; Varvas, K; Brash, A. R.; Samel, N (2007). "A critical role of non-active site residues on cyclooxygenase helices 5 and 6 in the control of prostaglandin stereochemistry at carbon 15". Journal of Biological Chemistry. 282 (38): 28157–63. doi:10.1074/jbc.M704950200. PMID 17652088.
  15. 1 2 3 Muñoz-Garcia, A; Thomas, C. P.; Keeney, D. S.; Zheng, Y; Brash, A. R. (2014). "The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1841 (3): 401–8. doi:10.1016/j.bbalip.2013.08.020. PMC 4116325Freely accessible. PMID 24021977.
  16. ↑ Krieg, P; Fürstenberger, G (2014). "The role of lipoxygenases in epidermis". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1841 (3): 390–400. doi:10.1016/j.bbalip.2013.08.005. PMID 23954555.
  17. ↑ Nigam, S; Patabhiraman, S; Ciccoli, R; Ishdorj, G; Schwarz, K; Petrucev, B; Kühn, H; Haeggström, J. Z. (2004). "The rat leukocyte-type 12-lipoxygenase exhibits an intrinsic hepoxilin A3 synthase activity". Journal of Biological Chemistry. 279 (28): 29023–30. doi:10.1074/jbc.M307576200. PMID 15123652.
  18. ↑ Gregus, A. M.; Dumlao, D. S.; Wei, S. C.; Norris, P. C.; Catella, L. C.; Meyerstein, F. G.; Buczynski, M. W.; Steinauer, J. J.; Fitzsimmons, B. L.; Yaksh, T. L.; Dennis, E. A. (2013). "Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia". The FASEB Journal. 27 (5): 1939–49. doi:10.1096/fj.12-217414. PMC 3633813Freely accessible. PMID 23382512.
  19. ↑ Stenson, W. F.; Parker, C. W. (1979). "12-L-hydroxy-5,8,10,14-eicosatetraenoic acid, a chemotactic fatty acid, is incorporated into neutrophil phospholipids and triglyceride". Prostaglandins. 18 (2): 285–92. doi:10.1016/0090-6980(79)90115-1. PMID 118490.
  20. ↑ Antón, R; Camacho, M; Puig, L; Vila, L (2002). "Hepoxilin B3 and its enzymatically formed derivative trioxilin B3 are incorporated into phospholipids in psoriatic lesions". Journal of Investigative Dermatology. 118 (1): 139–46. doi:10.1046/j.0022-202x.2001.01593.x. PMID 11851887.
  21. ↑ Joulain, C; Meskini, N; Anker, G; Lagarde, M; Prigent, A. F. (1995). "Esterification of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid into the phospholipids of human peripheral blood mononuclear cells: Inhibition of the proliferative response". Journal of Cellular Physiology. 164 (1): 154–63. doi:10.1002/jcp.1041640120. PMID 7790387.
  22. 1 2 Powell, W. S.; Rokach, J (2015). "Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1851 (4): 340–55. doi:10.1016/j.bbalip.2014.10.008. PMID 25449650.
  23. 1 2 3 4 Guo, Y; Zhang, W; Giroux, C; Cai, Y; Ekambaram, P; Dilly, A. K.; Hsu, A; Zhou, S; Maddipati, K. R.; Liu, J; Joshi, S; Tucker, S. C.; Lee, M. J.; Honn, K. V. (2011). "Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid". Journal of Biological Chemistry. 286 (39): 33832–40. doi:10.1074/jbc.M110.216564. PMC 3190773Freely accessible. PMID 21712392.
  24. ↑ Yokomizo, T; Kato, K; Hagiya, H; Izumi, T; Shimizu, T (2001). "Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2". Journal of Biological Chemistry. 276 (15): 12454–9. doi:10.1074/jbc.M011361200. PMID 11278893.
  25. ↑ Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Martin, L. D.; Webb, E. F.; Tzimas, M. N.; Breton, J. J.; Chabot-Fletcher, M; Underwood, D. C.; Hay, D. W.; Kingsbury, W. D.; Chambers, P. A.; Pendrak, I; Jakas, D. R.; Sathe, G. M.; Van Horn, S; Daines, R. A.; Griswold, D. E. (1999). "In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity". Prostaglandins, leukotrienes, and essential fatty acids. 61 (1): 55–64. doi:10.1054/plef.1999.0074. PMID 10477044.
  26. ↑ Naccache, P. H.; Leblanc, Y; Rokach, J; Patrignani, P; Fruteau De Laclos, B; Borgeat, P (1991). "Calcium mobilization and right-angle light scatter responses to 12-oxo-derivatives of arachidonic acid in neutrophils: Evidence for the involvement of the leukotriene B4 receptor". Biochimica et biophysica acta. 1133 (1): 102–6. doi:10.1016/0167-4889(91)90247-u. PMID 1661162.
  27. ↑ O'Flaherty, J. T.; Cordes, J. F.; Lee, S. L.; Samuel, M; Thomas, M. J. (1994). "Chemical and biological characterization of oxo-eicosatetraenoic acids". Biochimica et biophysica acta. 1201 (3): 505–15. doi:10.1016/0304-4165(94)90083-3. PMID 7803484.
  28. ↑ Yokomizo, T; Kato, K; Hagiya, H; Izumi, T; Shimizu, T (2001). "Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2". Journal of Biological Chemistry. 276 (15): 12454–9. doi:10.1074/jbc.M011361200. PMID 11278893.
  29. 1 2 3 Kim, H. J.; Kim, D. K.; Kim, H; Koh, J. Y.; Kim, K. M.; Noh, M. S.; Lee, S; Kim, S; Park, S. H.; Kim, J. J.; Kim, S. Y.; Lee, C. H. (2008). "Involvement of the BLT2 receptor in the itch-associated scratching induced by 12-(S)-lipoxygenase products in ICR mice". British Journal of Pharmacology. 154 (5): 1073–8. doi:10.1038/bjp.2008.220. PMC 2451041Freely accessible. PMID 18536755.
  30. ↑ Fretland, D. J.; Anglin, C. P.; Bremer, M; Isakson, P; Widomski, D. L.; Paulson, S. K.; Docter, S. H.; Djuric, S. W.; Penning, T. D.; Yu, S (1995). "Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: Impact upon leukotriene B4- and 12(R)-HETE-mediated events". Inflammation. 19 (2): 193–205. doi:10.1007/bf01534461. PMID 7601505.
  31. ↑ Kim, G. Y.; Lee, J. W.; Cho, S. H.; Seo, J. M.; Kim, J. H. (2009). "Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis". Arteriosclerosis, Thrombosis, and Vascular Biology. 29 (6): 915–20. doi:10.1161/ATVBAHA.109.185793. PMID 19286633.
  32. ↑ Yokomizo, T; Kato, K; Hagiya, H; Izumi, T; Shimizu, T (2001). "Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2". Journal of Biological Chemistry. 276 (15): 12454–9. doi:10.1074/jbc.M011361200. PMID 11278893.
  33. ↑ Okuno, T; Iizuka, Y; Okazaki, H; Yokomizo, T; Taguchi, R; Shimizu, T (2008). "12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2". The Journal of Experimental Medicine. 205 (4): 759–66. doi:10.1084/jem.20072329. PMC 2292216Freely accessible. PMID 18378794.
  34. ↑ Mais, D. E.; Saussy Jr, D. L.; Magee, D. E.; Bowling, N. L. (1990). "Interaction of 5-HETE, 12-HETE, 15-HETE and 5,12-diHETE at the human platelet thromboxane A2/prostaglandin H2 receptor". Eicosanoids. 3 (2): 121–4. PMID 2169775.
  35. ↑ Fonlupt, P; Croset, M; Lagarde, M (1991). "12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets". Thrombosis research. 63 (2): 239–48. doi:10.1016/0049-3848(91)90287-7. PMID 1837628.
  36. ↑ Siangjong, L; Gauthier, K. M.; Pfister, S. L.; Smyth, E. M.; Campbell, W. B. (2013). "Endothelial 12(S)-HETE vasorelaxation is mediated by thromboxane receptor inhibition in mouse mesenteric arteries". AJP: Heart and Circulatory Physiology. 304 (3): H382–92. doi:10.1152/ajpheart.00690.2012. PMC 3774504Freely accessible. PMID 23203967.
  37. ↑ Herbertsson H, Kühme T, Hammarström S (Jul 1999). "The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit". Archives of Biochemistry and Biophysics. 367 (1): 33–8. doi:10.1006/abbi.1999.1233. PMID 10375396.
  38. ↑ Sahu, S; Lynn, W. S. (1977). "Lipid chemotaxins isolated from culture filtrates of Escherichia coli and from oxidized lipids". Inflammation. 2 (1): 47–54. doi:10.1007/bf00920874. PMID 367961.
  39. ↑ Goetzl, E. J.; Hill, H. R.; Gorman, R. R. (1980). "Unique aspects of the modulation of human neutrophil function by 12-L-hydroperoxy-5,8,10,14-eicosatetraenoic acid". Prostaglandins. 19 (1): 71–85. doi:10.1016/0090-6980(80)90155-0. PMID 6247746.
  40. ↑ Palmer, R. M.; Stepney, R. J.; Higgs, G. A.; Eakins, K. E. (1980). "Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species". Prostaglandins. 20 (2): 411–8. doi:10.1016/s0090-6980(80)80058-x. PMID 6251514.
  41. ↑ O'Flaherty, J. T.; Thomas, M. J.; Lees, C. J.; McCall, C. E. (1981). "Neutrophil-aggregating activity of monohydroxyeicosatetraenoic acids". The American journal of pathology. 104 (1): 55–62. PMC 1903737Freely accessible. PMID 7258296.
  42. ↑ Huber, J; Fürnkranz, A; Bochkov, V. N.; Patricia, M. K.; Lee, H; Hedrick, C. C.; Berliner, J. A.; Binder, B. R.; Leitinger, N (2006). "Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase". The Journal of Lipid Research. 47 (5): 1054–62. doi:10.1194/jlr.M500555-JLR200. PMID 16461778.
  43. ↑ Honda, H. M.; Leitinger, N; Frankel, M; Goldhaber, J. I.; Natarajan, R; Nadler, J. L.; Weiss, J. N.; Berliner, J. A. (1999). "Induction of monocyte binding to endothelial cells by MM-LDL: Role of lipoxygenase metabolites". Arteriosclerosis, thrombosis, and vascular biology. 19 (3): 680–6. doi:10.1161/01.atv.19.3.680. PMID 10073973.
  44. ↑ Yoo, H; Kim, S. J.; Kim, Y; Lee, H; Kim, T. Y. (2007). "Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways". The International Journal of Biochemistry & Cell Biology. 39 (6): 1248–59. doi:10.1016/j.biocel.2007.04.009. PMID 17521953.
  45. ↑ Dowd, P. M.; Kobza Black, A; Woollard, P. M.; Camp, R. D.; Greaves, M. W. (1985). "Cutaneous responses to 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE)". The Journal of Investigative Dermatology. 84 (6): 537–41. doi:10.1111/1523-1747.ep12273537. PMID 3998504.
  46. ↑ Wollard, P. M.; Cunnigham, F. M.; Murphy, G. M.; Camp, R. D.; Derm, F. F.; Greaves, M. W. (1989). "A comparison of the proinflammatory effects of 12(R)- and 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid in human skin". Prostaglandins. 38 (4): 465–71. doi:10.1016/0090-6980(89)90129-9. PMID 2813813.
  47. 1 2 Voorhees, J. J. (1983). "Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses". Archives of dermatology. 119 (7): 541–7. doi:10.1001/archderm.1983.01650310003001. PMID 6305285.
  48. ↑ Wollard, P. M.; Cunnigham, F. M.; Murphy, G. M.; Camp, R. D.; Derm, F. F.; Greaves, M. W. (1989). "A comparison of the proinflammatory effects of 12(R)- and 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid in human skin". Prostaglandins. 38 (4): 465–71. doi:10.1016/0090-6980(89)90129-9. PMID 2813813.
  49. ↑ Kragballe, K; Voorhees, J. J. (1985). "Arachidonic acid in psoriasis. Pathogenic role and pharmacological regulation". Acta dermato-venereologica. Supplementum. 120: 12–7. PMID 3010612.
  50. ↑ Fretland, D. J.; Anglin, C. P.; Bremer, M; Isakson, P; Widomski, D. L.; Paulson, S. K.; Docter, S. H.; Djuric, S. W.; Penning, T. D.; Yu, S (1995). "Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: Impact upon leukotriene B4- and 12(R)-HETE-mediated events". Inflammation. 19 (2): 193–205. doi:10.1007/bf01534461. PMID 7601505.
  51. ↑ Fox, T; Gotlinger, K. H.; Dunn, M. W.; Lee, O. L.; Milman, T; Zaidman, G; Schwartzman, M. L.; Bellner, L (2013). "Dysregulated heme oxygenase-ferritin system in pterygium pathogenesis". Cornea. 32 (9): 1276–82. doi:10.1097/ICO.0b013e3182936915. PMC 3740074Freely accessible. PMID 23792437.
  52. ↑ Kim, D. K.; Kim, H. J.; Sung, K. S.; Kim, H; Cho, S. A.; Kim, K. M.; Lee, C. H.; Kim, J. J. (2007). "12(S)-HPETE induces itch-associated scratchings in mice". European Journal of Pharmacology. 554 (1): 30–3. doi:10.1016/j.ejphar.2006.09.057. PMID 17112507.
  53. ↑ Yang, P; Cartwright, C. A.; Li, J; Wen, S; Prokhorova, I. N.; Shureiqi, I; Troncoso, P; Navone, N. M.; Newman, R. A.; Kim, J (2012). "Arachidonic acid metabolism in human prostate cancer". International Journal of Oncology. 41 (4): 1495–503. doi:10.3892/ijo.2012.1588. PMC 3982713Freely accessible. PMID 22895552.
  54. ↑ Pidgeon, G. P.; Tang, K; Cai, Y. L.; Piasentin, E; Honn, K. V. (2003). "Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression". Cancer research. 63 (14): 4258–67. PMID 12874035.
  55. ↑ Yang, P; Cartwright, C; Chan, D; Vijjeswarapu, M; Ding, J; Newman, R. A. (2007). "Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation". Cancer biology & therapy. 6 (2): 228–36. doi:10.4161/cbt.6.2.3624. PMID 17218785.
  56. ↑ Pidgeon, G. P.; Kandouz, M; Meram, A; Honn, K. V. (2002). "Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells". Cancer research. 62 (9): 2721–7. PMID 11980674.
  57. ↑ PC3 and LNCaP
  58. ↑ Nie, D; Krishnamoorthy, S; Jin, R; Tang, K; Chen, Y; Qiao, Y; Zacharek, A; Guo, Y; Milanini, J; Pages, G; Honn, K. V. (2006). "Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells". Journal of Biological Chemistry. 281 (27): 18601–9. doi:10.1074/jbc.M601887200. PMID 16638750.
  59. ↑ Lee, J. W.; Kim, G. Y.; Kim, J. H. (2012). "Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression". Biochemical and Biophysical Research Communications. 420 (2): 428–33. doi:10.1016/j.bbrc.2012.03.012. PMID 22426480.
  60. 1 2 Lee, J. W.; Kim, J. H. (2013). "Activation of the leukotriene B4 receptor 2-reactive oxygen species (BLT2-ROS) cascade following detachment confers anoikis resistance in prostate cancer cells". Journal of Biological Chemistry. 288 (42): 30054–63. doi:10.1074/jbc.M113.481283. PMC 3798474Freely accessible. PMID 23986446.
  61. ↑ Xu, X. M.; Yuan, G. J.; Deng, J. J.; Guo, H. T.; Xiang, M; Yang, F; Ge, W; Chen, S. Y. (2012). "Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo". Hepatobiliary & pancreatic diseases international : HBPD INT. 11 (2): 193–202. doi:10.1016/s1499-3872(12)60147-7. PMID 22484589.
  62. ↑ Fitian, A. I.; Nelson, D. R.; Liu, C; Xu, Y; Ararat, M; Cabrera, R (2014). "Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS". Liver International. 34 (9): 1428–44. doi:10.1111/liv.12541. PMC 4169337Freely accessible. PMID 24661807.
  63. ↑ Bortuzzo, C; Hanif, R; Kashfi, K; Staiano-Coico, L; Shiff, S. J.; Rigas, B (1996). "The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells". Biochimica et biophysica acta. 1300 (3): 240–6. doi:10.1016/0005-2760(96)00003-3. PMID 8679690.
  64. 1 2 Cabral, M; Martín-Venegas, R; Moreno, J. J. (2013). "Role of arachidonic acid metabolites on the control of non-differentiated intestinal epithelial cell growth". The International Journal of Biochemistry & Cell Biology. 45 (8): 1620–8. doi:10.1016/j.biocel.2013.05.009. PMID 23685077.
  65. ↑ Kudryavtsev, I. A.; Gudkova, M. V.; Pavlova, O. M.; Oreshkin, A. E.; Myasishcheva, N. V. (2005). "Lipoxygenase pathway of arachidonic acid metabolism in growth control of tumor cells of different type". Biochemistry. Biokhimiia. 70 (12): 1396–403. doi:10.1007/s10541-005-0275-0. PMID 16417464.
  66. ↑ Tong, W. G.; Ding, X. Z.; Adrian, T. E. (2002). "The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells". Biochemical and biophysical research communications. 296 (4): 942–8. doi:10.1016/s0006-291x(02)02014-4. PMID 12200139.
  67. ↑ Vonach, C; Viola, K; Giessrigl, B; Huttary, N; Raab, I; Kalt, R; Krieger, S; Vo, T. P.; Madlener, S; Bauer, S; Marian, B; Hämmerle, M; Kretschy, N; Teichmann, M; Hantusch, B; Stary, S; Unger, C; Seelinger, M; Eger, A; Mader, R; Jäger, W; Schmidt, W; Grusch, M; Dolznig, H; Mikulits, W; Krupitza, G (2011). "NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells". British Journal of Cancer. 105 (2): 263–71. doi:10.1038/bjc.2011.194. PMC 3142797Freely accessible. PMID 21629247.
  68. ↑ Winer, I; Normolle, D. P.; Shureiqi, I; Sondak, V. K.; Johnson, T; Su, L; Brenner, D. E. (2002). "Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis". Melanoma research. 12 (5): 429–34. doi:10.1097/00008390-200209000-00003. PMID 12394183.
  69. ↑ Guo, A. M.; Liu, X; Al-Wahab, Z; Maddippati, K. R.; Ali-Fehmi, R; Scicli, A. G.; Munkarah, A. R. (2011). "Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival". Cancer Chemotherapy and Pharmacology. 68 (5): 1273–83. doi:10.1007/s00280-011-1595-y. PMID 21442472.
  70. ↑ Ding, X. Z.; Iversen, P; Cluck, M. W.; Knezetic, J. A.; Adrian, T. E. (1999). "Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells". Biochemical and Biophysical Research Communications. 261 (1): 218–23. doi:10.1006/bbrc.1999.1012. PMID 10405349.
  71. ↑ Ding, X. Z.; Tong, W. G.; Adrian, T. E. (2001). "12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation". International Journal of Cancer. 94 (5): 630–6. doi:10.1002/ijc.1527. PMID 11745456.
  72. 1 2 Seo, J. M.; Cho, K. J.; Kim, E. Y.; Choi, M. H.; Chung, B. C.; Kim, J. H. (2011). "Up-regulation of BLT2 is critical for the survival of bladder cancer cells". Experimental & Molecular Medicine. 43 (3): 129–37. doi:10.3858/emm.2011.43.3.014. PMC 3068295Freely accessible. PMID 21252614.
  73. ↑ Cho, N. K.; Joo, Y. C.; Wei, J. D.; Park, J. I.; Kim, J. H. (2013). "BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development". American journal of cancer research. 3 (4): 347–55. PMC 3744015Freely accessible. PMID 23977445.
  74. ↑ Hennig, R; Osman, T; Esposito, I; Giese, N; Rao, S. M.; Ding, X. Z.; Tong, W. G.; Büchler, M. W.; Yokomizo, T; Friess, H; Adrian, T. E. (2008). "BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation". British Journal of Cancer. 99 (7): 1064–73. doi:10.1038/sj.bjc.6604655. PMC 2567081Freely accessible. PMID 18781173.
  75. ↑ Chen, M; Yang, Z. D.; Smith, K. M.; Carter, J. D.; Nadler, J. L. (2005). "Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity". Diabetologia. 48 (3): 486–95. doi:10.1007/s00125-005-1673-y. PMID 15729574.
  76. ↑ Ma, K; Nunemaker, C. S.; Wu, R; Chakrabarti, S. K.; Taylor-Fishwick, D. A.; Nadler, J. L. (2010). "12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets". The Journal of Clinical Endocrinology & Metabolism. 95 (2): 887–93. doi:10.1210/jc.2009-1102. PMC 2840856Freely accessible. PMID 20089617.
  77. ↑ Weaver, J. R.; Holman, T. R.; Imai, Y; Jadhav, A; Kenyon, V; Maloney, D. J.; Nadler, J. L.; Rai, G; Simeonov, A; Taylor-Fishwick, D. A. (2012). "Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction". Molecular and Cellular Endocrinology. 358 (1): 88–95. doi:10.1016/j.mce.2012.03.004. PMID 22502743.
  78. ↑ Bleich, D; Chen, S; Zipser, B; Sun, D; Funk, C. D.; Nadler, J. L. (1999). "Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice". Journal of Clinical Investigation. 103 (10): 1431–6. doi:10.1172/JCI5241. PMC 408453Freely accessible. PMID 10330425.
  79. ↑ Zhou, W; Wang, X. L.; Kaduce, T. L.; Spector, A. A.; Lee, H. C. (2005). "Impaired arachidonic acid-mediated dilation of small mesenteric arteries in Zucker diabetic fatty rats". AJP: Heart and Circulatory Physiology. 288 (5): H2210–8. doi:10.1152/ajpheart.00704.2004. PMID 15626691.
  80. ↑ Miller, A. W.; Katakam, P. V.; Lee, H. C.; Tulbert, C. D.; Busija, D. W.; Weintraub, N. L. (2003). "Arachidonic acid-induced vasodilation of rat small mesenteric arteries is lipoxygenase-dependent". Journal of Pharmacology and Experimental Therapeutics. 304 (1): 139–44. doi:10.1124/jpet.102.041780. PMID 12490584.
  81. ↑ Zink, M. H.; Oltman, C. L.; Lu, T; Katakam, P. V.; Kaduce, T. L.; Lee, H; Dellsperger, K. C.; Spector, A. A.; Myers, P. R.; Weintraub, N. L. (2001). "12-lipoxygenase in porcine coronary microcirculation: Implications for coronary vasoregulation". American journal of physiology. Heart and circulatory physiology. 280 (2): H693–704. PMID 11158968.
  82. ↑ Faraci, F. M.; Sobey, C. G.; Chrissobolis, S; Lund, D. D.; Heistad, D. D.; Weintraub, N. L. (2001). "Arachidonate dilates basilar artery by lipoxygenase-dependent mechanism and activation of K(+) channels". American journal of physiology. Regulatory, integrative and comparative physiology. 281 (1): R246–53. PMID 11404300.
  83. ↑ Ma, Y. H.; Harder, D. R.; Clark, J. E.; Roman, R. J. (1991). "Effects of 12-HETE on isolated dog renal arcuate arteries". The American journal of physiology. 261 (2 Pt 2): H451–6. PMID 1908641.
  84. ↑ Kisch, E. S.; Jaffe, A; Knoll, E; Stern, N (1997). "Role of the lipoxygenase pathway in angiotensin II-induced vasoconstriction in the human placenta". Hypertension. 29 (3): 796–801. doi:10.1161/01.hyp.29.3.796. PMID 9052898.
  85. ↑ Porro, B; Songia, P; Squellerio, I; Tremoli, E; Cavalca, V (2014). "Analysis, physiological and clinical significance of 12-HETE: A neglected platelet-derived 12-lipoxygenase product". Journal of Chromatography B. 964: 26–40. doi:10.1016/j.jchromb.2014.03.015. PMID 24685839.
This article is issued from Wikipedia - version of the 11/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.